Skip to main content
Eligibility
for people ages 6 years and up
Location
at Oakland, California and other locations
Dates
study started
estimated completion:

Description

Summary

This is an open-label extension study for patients who complete a Phase 3, placebo-controlled study of ataluren in patients with nonsense mutation cystic fibrosis (nmCF) not receiving chronic inhaled aminoglycosides.

Official Title

A Phase 3 Extension Study of Ataluren (PTC124) in Patients With Nonsense Mutation Cystic Fibrosis

Keywords

Cystic Fibrosis

Eligibility

You can join if…

Open to people ages 6 years and up

  • Completion of study treatment (placebo or active) in the previous Phase 3,double-blind study protocol (Protocol PTC124-GD-021-CF)

You CAN'T join if...

  • Ongoing participation in any other therapeutic clinical trial

Locations

  • Stanford University-Children's Hospital
    Palo Alto, California, 94304, USA
  • Miller Children's Hospital Long Beach
    Long Beach, California, 90806, USA
  • Children's Hospital Los Angeles
    Los Angeles, California, 90027, USA

Details

Status
accepting new patients by invitation only
Start Date
Completion Date
(estimated)
Sponsor
PTC Therapeutics
ID
NCT02456103
Phase
Phase 3
Study Type
Interventional
Last Updated
May 2015